Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases

Practical Radiation Oncology

Volumn 6, Issue 2, 2016, Pages 86-95

  Goodman, Benjamin D ^a   Mannina, Edward M ^a   Althouse, Sandra K ^a   Maluccio, Mary A ^a   Cárdenes, Higinia R ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Schneck Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; DEATH; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; LIVER METASTASIS; LIVER OLIGOMETASTASIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLEURA EFFUSION; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION RESPONSE; RADIATION SAFETY; SOLID TUMOR; STEREOTACTIC BODY RADIATION THERAPY; THORAX PAIN; TREATMENT RESPONSE; ADVERSE EFFECTS; LIVER NEOPLASMS; METASTASIS; MIDDLE AGED; PROCEDURES; RADIOSURGERY; SECONDARY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RADIOSURGERY; TREATMENT OUTCOME;

EID: 84959147800     PISSN: 18798500     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prro.2015.10.011     Document Type: Article

References (47)

1. Hellman S., Weichselbaum R.R. Oligometastases. J Clin Oncol 1995, 13:8-10.
2. Weichselbaum R.R., Hellman S. Oligometastases revisited. Nat Rev Clin Oncol 2011, 8:378-382.
3. Mohammad W.M., Balaa F.K. Surgical management of colorectal liver metastases. Clin Colon Rectal Surg 2009, 22:225-232.
4. Haddad A.J., Bani Hani M., Pawlik T.M., Pawlik T.M., Cunningham S.C. Colorectal liver metastases. Int J Surg Oncol 2011, 2011:285840.
5. Adam R., Chiche L., Aloia T., Elias D., Salmon R., Rivoire M., et al. Hepatic resection for noncolorectal nonendocrine liver metastases: Analysis of 1,452 patients and development of a prognostic model. Ann Surg 2006, 244:524-535.
6. Goodman K.A., Wiegner E.A., Maturen K.E., Zhang Z., Mo Q., Yang G., et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys 2010, 78:486-493.
7. Herfarth K.K., Debus J., Lohr F., Bahner M.L., Rhein B., Fritz P., et al. Stereotactic single-dose radiation therapy of liver tumors: Results of a phase I/II trial. J Clin Oncol 2001, 19:164-170.
8. Hoyer M., Swaminath A., Bydder S., Lock M., Méndez Romero A., Kavanagh B., et al. Radiotherapy for liver metastases: A review of evidence. Int J Radiat Oncol Biol Phys 2012, 82:1047-1057.
9. Lee M.T., Kim J.J., Dinniwell R., Brierley J., Lockwood G., Wong R., et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 2009, 27:1585-1591.
10. Mendez Romero A., Wunderink W., Hussain S.M., Brierley J., Lockwood G., Wong R., et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase I-II study. Acta Oncol 2006, 45:831-837.
11. Rusthoven K.E., Kavanagh B.D., Cardenes H., Stieber V.W., Burri S.H., Feigenberg S.J., et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009, 27:1572-1578.
12. Cardenes H.R., Price T.R., Perkins S.M., Maluccio M., Kwo P., Breen T.E., et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol 2010, 12:218-825.
13. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
14. National Cancer Institute, National Institutes of Health Common terminology criteria for adverse events (CTCAE), version 4.0 2009, US Department of Health and Human Services, Bethesda, MD, Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference:5x7.pdf. Accessed October 28, 2015.
15. Macdermed D.M., Weichselbaum R.R., Salama J.K. A rationale for the targeted treatment of oligometastases with radiotherapy. J Surg Oncol 2008, 98:202-206.
16. Ito K., Govindarajan A., Ito H., Fong Y. Surgical treatment of hepatic colorectal metastasis: Evolving role in the setting of improving systemic therapies and ablative treatments in the 21st century. Cancer J 2010, 16:103-110.
17. Nordlinger B., Guiguet M., Vaillant J.C., Balladur P., Boudjema K., Bachellier P., et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996, 77:1254-1262.
18. Adam R., Avisar E., Ariche A., Giachetti S., Azoulay D., Castaing D., et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001, 8:347-353.
19. House MG, Ito H., Gonen M., Fong Y., Allen P.J., DeMatteo R.P., et al. Survival after hepatic resection for metastatic colorectal cancer: Trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg 2010, 210:744-755.
20. Nathan H., de Jong M.C., Pulitano C., Ribero D., Strub J., Mentha G., et al. Conditional survival after surgical resection of colorectal liver metastasis: An international multi-institutional analysis of 949 patients. J Am Coll Surg 2010, 210:755-766.
21. Fong Y., Fortner J., Sun R.L., Brennan M.F., Blumgart L.H. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 1999, 230:309-321.
22. Adam R., Frilling A., Elias D., Laurent C., Ramos E., Capussotti L., et al. Liver resection of colorectal metastases in elderly patients. Br J Surg 2010, 97:366-376.
23. Douillard J.Y., Siena S., Cassidy J., Tabernero J., Burkes R., Barugel M., et al. Final results from PRIME: Randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 2014, 25:1346-1355.
24. Saltz L.B., Clarke S., Diaz-Rubio E., Scheithauer W., Figer A., Wong R., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008, 26:2013-2019.
25. Van Cutsem E., Kohne C.H., Hitre E., Zaluski J., Chang Chien C.R., Makhson A., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360:1408-1417.
26. Park J., Chen Y.J., Lu W.P., Fong Y. The evolution of liver-directed treatments for hepatic colorectal metastases. Oncology (Williston Park) 2014, 28:991-1003.
27. Simmonds P.C., Primrose J.N., Colquitt J.L., Garden O.J., Poston G.J., Rees M. Surgical resection of hepatic metastases from colorectal cancer: A systematic review of published studies. Br J Cancer 2006, 94:982-999.
28. Kennedy A.S., Coldwell D., Nutting C., Murthy R., Wertman D.E., Loehr S.P., et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: Modern USA experience. Int J Radiat Oncol Biol Phys 2006, 65:412-425.
29. Dawson L.A., McGinn C.J., Normolle D., Ten Haken R.K., Walker S., Ensminger W., et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 2000, 18:2210-2218.
30. Lawrence T.S., Robertson J.M., Anscher M.S., Jirtle R.L., Ensminger W.D., Fajardo L.F. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 1995, 31:1237-1248.
31. Blomgren H., Lax I., Naslund I., Svanström R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol 1995, 34:861-870.
32. Blomgren H., Lax I., Göranson H., Kræpelien T., Nilsson B., Näslund I., et al. Radiosurgery for tumors in the body: Clinical experience using a new method. J Radiosurg 1998, 1:63-74.
33. Herfarth K.K., Hof H., Bahner M.L., Lohr F., Höss A., van Kaick G., et al. Assessment of focal liver reaction by multiphasic CT after stereotactic single-dose radiotherapy of liver tumors. Int J Radiat Oncol Biol Phys 2003, 57:444-451.
34. Hoyer M., Roed H., Traberg Hansen A., Lohr F., Höss A., van Kaick G., et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 2006, 45:823-830.
35. Nair V.J., Pantarotto J.R. Treatment of metastatic liver tumors using stereotactic ablative radiotherapy. World J Radiol 2014, 6:18-25.
36. Dawood O., Mahadevan A., Goodman K.A. Stereotactic body radiation therapy for liver metastases. Eur J Cancer 2009, 45:2947-2959.
37. Milano M.T., Katz A.W., Muhs A.G., Philip A., Buchholz D.J., Schell M.C., et al. A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer 2008, 112:650-658.
38. Rule W., Timmerman R., Tong L., Abdulrahman R., Meyer J., Boike T., et al. Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol 2011, 18:1081-1087.
39. Schefter T.E., Kavanagh B.D., Timmerman R.D., Cardenes H.R., Baron A., Gaspar L.E. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys 2005, 62:1371-1378.
40. Scorsetti M., Arcangeli S., Tozzi A., Comito T., Alongi F., Navarria P., et al. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys 2013, 86:336-342.
41. Wulf J., Guckenberger M., Haedinger U., Oppitz U., Mueller G., Baier K., et al. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol 2006, 45:838-847.
42. Wulf J., Hadinger U., Oppitz U., Thiele W., Ness-Dourdoumas R., Flentje M. Stereotactic radiotherapy of targets in the lung and liver. Strahlenther Onkol 2001, 177:645-655.
43. Yuan Z.Y., Meng M.B., Liu C.L., Wang H.H., Jiang C., Song Y.C., et al. Stereotactic body radiation therapy using the CyberKnife((R)) system for patients with liver metastases. Onco Targets Ther 2014, 7:915-923.
44. Chang D.T., Swaminath A., Kozak M., Weintraub J., Koong A.C., Kim J., et al. Stereotactic body radiotherapy for colorectal liver metastases: A pooled analysis. Cancer 2011, 117:4060-4069.
45. McCammon R., Schefter T.E., Gaspar L.E., Zaemisch R., Gravdahl D., Kavanagh B. Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2009, 73:112-118.
46. Andolino D.L., Forquer J.A., Henderson M.A., Barriger R.B., Shapiro R.H., Brabham J.G., et al. Chest wall toxicity after stereotactic body radiotherapy for malignant lesions of the lung and liver. Int J Radiat Oncol Biol Phys 2011, 80:692-697.
47. van der Pool A.E., Mendez Romero A., Wunderink W., Heijmen B.J., Levendag P.C., Verhoef C., et al. Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg 2010, 97:377-382.